pantoprazole has been researched along with Atherogenesis in 1 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ma, Y | 1 |
| Li, S | 1 |
| Yang, H | 1 |
| Zhang, Y | 1 |
| Li, H | 1 |
| Zhou, L | 1 |
| Lin, J | 1 |
| Chen, Y | 1 |
| Hou, Y | 1 |
| Zhang, X | 1 |
| Liu, T | 1 |
| Zhou, X | 1 |
| Wang, Y | 1 |
1 other study available for pantoprazole and Atherogenesis
| Article | Year |
|---|---|
Acid suppressants use and risk of atherosclerotic cardiovascular disease in middle-aged and older adults.
Topics: Aged; Antihypertensive Agents; Atherosclerosis; Cardiovascular Diseases; Histamine; Humans; Lansopra | 2022 |